Previous 10 | Next 10 |
home / stock / azn / azn articles
AstraZeneca (NASDAQ:AZN) has declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an “excess of updated vaccines.”...
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 20...
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...
AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study. The results showed that Enhertu (t...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
As of April 26, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in t...
Thursday, April 25th, 2024 Pre-market futures are plummeting at this hour. We began the early trading session down anyway, based on earnings disapp...
U.S. stocks were lower, with the Dow Jones falling over 600 points on Thursday. Shares of Sanofi SA (NASDAQ:SNY) rose sharply during Thursday'...
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...